Terms: = Kidney tumors AND ARNT, HIF1BETA, 405, ENSG00000143437, P27540, HIF-1beta, HIF1B, TANGO AND Treatment
31 results:
1. Computed tomography-based radiomics to assess risk stratification in pediatric malignant peripheral neuroblastic tumors.
Wang X; Wang X; Wu T; Hu L; Xu M; Tang J; Li X; Zhong Y
Medicine (Baltimore); 2023 Nov; 102(47):e35690. PubMed ID: 38013377
[TBL] [Abstract] [Full Text] [Related]
2. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma.
Dizman N; Govindarajan A; Zengin ZB; Meza L; Tripathi N; Sayegh N; Castro DV; Chan EH; Lee KO; Prajapati S; Feng M; Loo V; Pace M; O'Brien S; Bailey E; Barragan-Carrillo R; Chehrazi-Raffle A; Hsu J; Li X; Agarwal N; Pal SK
Clin Genitourin Cancer; 2023 Oct; 21(5):530-536. PubMed ID: 37495481
[TBL] [Abstract] [Full Text] [Related]
3. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated tumors.
Suárez C; Vieito M; Valdivia A; González M; Carles J
Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
[TBL] [Abstract] [Full Text] [Related]
4. The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis.
Monteiro FSM; Soares A; Rizzo A; Santoni M; Mollica V; Grande E; Massari F
Clin Genitourin Cancer; 2023 Jun; 21(3):324-333. PubMed ID: 36823017
[TBL] [Abstract] [Full Text] [Related]
5. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Motzer RJ; Russo P; Grünwald V; Tomita Y; Zurawski B; Parikh O; Buti S; Barthélémy P; Goh JC; Ye D; Lingua A; Lattouf JB; Albigès L; George S; Shuch B; Sosman J; Staehler M; Vázquez Estévez S; Simsek B; Spiridigliozzi J; Chudnovsky A; Bex A
Lancet; 2023 Mar; 401(10379):821-832. PubMed ID: 36774933
[TBL] [Abstract] [Full Text] [Related]
6. Multi-level interaction between HIF and AHR transcriptional pathways in kidney carcinoma.
Lafleur VN; Halim S; Choudhry H; Ratcliffe PJ; Mole DR
Life Sci Alliance; 2023 Apr; 6(4):. PubMed ID: 36725335
[TBL] [Abstract] [Full Text] [Related]
7. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract] [Full Text] [Related]
8. THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND DRUGGING THE UNDRUGGABLE.
Kaelin WG
Trans Am Clin Climatol Assoc; 2022; 132():170-181. PubMed ID: 36196173
[TBL] [Abstract] [Full Text] [Related]
9. Clinical and oncological outcomes of open partial nephrectomy versus robot assisted partial nephrectomy over 15 years.
Audigé V; Baghli A; Hubert J; Mazeaud C; Larré S; Branchu B
J Robot Surg; 2023 Apr; 17(2):519-526. PubMed ID: 35851947
[TBL] [Abstract] [Full Text] [Related]
10. Significant co-expression of putative cancer stem cell markers, EpCAM and CD166, correlates with tumor stage and invasive behavior in colorectal cancer.
Kalantari E; Taheri T; Fata S; Abolhasani M; Mehrazma M; Madjd Z; Asgari M
World J Surg Oncol; 2022 Jan; 20(1):15. PubMed ID: 35016698
[TBL] [Abstract] [Full Text] [Related]
11. Percutaneous
Hong Y; Chen X; Wu M; Xi H; Hu J
J Endourol; 2021 Dec; 35(12):1793-1800. PubMed ID: 34036798
[No Abstract] [Full Text] [Related]
12. Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
Garon EB; Aerts J; Kim JS; Muehlenbein CE; Peterson P; Rizzo MT; Gadgeel SM
Lung Cancer; 2021 May; 155():53-60. PubMed ID: 33730652
[TBL] [Abstract] [Full Text] [Related]
13. HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
Courtney KD; Ma Y; Diaz de Leon A; Christie A; Xie Z; Woolford L; Singla N; Joyce A; Hill H; Madhuranthakam AJ; Yuan Q; Xi Y; Zhang Y; Chang J; Fatunde O; Arriaga Y; Frankel AE; Kalva S; Zhang S; McKenzie T; Reig Torras O; Figlin RA; Rini BI; McKay RM; Kapur P; Wang T; Pedrosa I; Brugarolas J
Clin Cancer Res; 2020 Feb; 26(4):793-803. PubMed ID: 31727677
[TBL] [Abstract] [Full Text] [Related]
14. Pharmacologic Targeting of Hypoxia-Inducible Factors.
Semenza GL
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():379-403. PubMed ID: 30625281
[TBL] [Abstract] [Full Text] [Related]
15. The association of renal cell carcinoma with gastrointestinal stromal tumors.
Mendonca SJ; Sanchez A; Blum KA; Ghanaat M; Kashan MY; Benfante N; Russo P; Coleman JA; Crago AM; Hakimi AA
J Surg Oncol; 2018 Jun; 117(8):1716-1720. PubMed ID: 29878354
[TBL] [Abstract] [Full Text] [Related]
16. Estimation of Future Cancer Burden Among Rescue and Recovery Workers Exposed to the World Trade Center Disaster.
Singh A; Zeig-Owens R; Moir W; Hall CB; Schwartz T; Vossbrinck M; Jaber N; Webber MP; Kelly KJ; Ortiz V; Koffler E; Prezant DJ
JAMA Oncol; 2018 Jun; 4(6):828-831. PubMed ID: 29710126
[TBL] [Abstract] [Full Text] [Related]
17. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.
Martínez-Sáez O; Gajate Borau P; Alonso-Gordoa T; Molina-Cerrillo J; Grande E
Crit Rev Oncol Hematol; 2017 Mar; 111():117-123. PubMed ID: 28259286
[TBL] [Abstract] [Full Text] [Related]
18. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract] [Full Text] [Related]
19. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract] [Full Text] [Related]
20. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.
Wallace EM; Rizzi JP; Han G; Wehn PM; Cao Z; Du X; Cheng T; Czerwinski RM; Dixon DD; Goggin BS; Grina JA; Halfmann MM; Maddie MA; Olive SR; Schlachter ST; Tan H; Wang B; Wang K; Xie S; Xu R; Yang H; Josey JA
Cancer Res; 2016 Sep; 76(18):5491-500. PubMed ID: 27635045
[TBL] [Abstract] [Full Text] [Related]
[Next]
